ReviewEuropean archives of psychiatry and clinical neuroscience2006
Tranylcypromine: new perspectives on an "old" drug.
Review in European archives of psychiatry and clinical neuroscience, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.Neuromolecular medicine · 2013Pooled it
- Unravelling the target landscape of tranylcypromines for new drug discovery.Acta pharmaceutica Sinica. B · 2025Review
- Classics in Chemical Neuroscience: Tianeptine.ACS chemical neuroscience · 2024Review
- Identifying Malnutrition Risk in the Elderly: A Single- and Multi-Parameter Approach.Nutrients · 2024Article
- An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.Genes · 2023Review
- New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity.International journal of molecular sciences · 2022Article
- The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni.PLoS neglected tropical diseases · 2020Article
- Effects of in vitro Amitriptyline, Fluoxetine, Tranylcypromine and Venlafaxine on Saphenous Vein Grafts.Brazilian journal of cardiovascular surgery · 2019Article
- Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury.Acta neuropathologica communications · 2018Article
- Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.Molecules (Basel, Switzerland) · 2017Review
- Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation.Psychiatry and clinical neurosciences · 2016Review
- Review
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Nature reviews. Drug discovery · 2014Review
- Revisiting the monoamine hypothesis of depression: a new perspective.Perspectives in medicinal chemistry · 2014Article
- Prostacyclin mediates endothelial COX-2-dependent neuroprotective effects during excitotoxic brain injury.Journal of inflammation research · 2014Article
- Natural Polyphenols Inhibit Lysine-Specific Demethylase-1Journal of biochemical and pharmacological research · 2013Article
- Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction.Nature medicine · 2013Article
- The GABAβ receptor as a target for antidepressant drug action.British journal of pharmacology · 2011Review
- Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The irreversible inhibitor of monoamine oxidase, tranylcypromine, is a potent antidepressant, but its use is limited to special indications due to side effects and dietary restrictions. The antidepressant action of tranylcypromine is not completely explainable by its effects on monoamine oxidase. Tranylcypromine also leads to an increase in brain trace amines, which are believed to play a key role in the pathophysiology of depression. It also affects other pathophysiological pathways associated with depression. Tranylcypromine treatment leads to an up-regulation of GABA(B)-receptors and modulates the phospholipid metabolism, which is essential for normal brain function. These findings implicate that the efficacy of tranylcypromine as an antidepressant may be due to its multiple actions within the human brain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.